Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
Purpose: Gadoxetic acid uptake on hepatobiliary phase MRI has been shown to correlate with ß-catenin mutation in patients with HCC, which is associated with resistance to certain therapies. This study aimed to evaluate the prognostic value of gadoxetic acid uptake on hepatobiliary phase MRI in patie...
| Autores: | , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/118732 |
| Acceso en línea: | https://hdl.handle.net/10171/118732 |
| Access Level: | acceso abierto |
| Palabra clave: | Gadoxetic acid Hepatocellular carcinoma Radioembolization Sorafenib WNT ß-Catenin Hepatología |
| id |
ES_f30bcbcaa150a9dbf8ad2e71867fdd4f |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/118732 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trialÖcal, O. (Osman)|||/items/e20f890d-387b-4b27-8cd2-bc265d1c07bbRössler, D. (Daniel)|||/items/dfe8430c-6249-4c20-a1c3-e208c2cdcbb8Gasbarrini, A. (Antonio)|||/items/abf16136-3e15-4dc4-898a-37218b06e35cBerg, T. (Thomas)|||/items/b24d8023-a52b-43bc-aae1-2eb6903e97a1Klümpen, H. (Heinz)|||/items/6bb3d4b6-7e18-4aee-82af-296199525b09Bargellini, I. (Irene)|||/items/2c302084-c5c3-4f12-8876-fc1da43d1c03Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16Delden, O.M. (Otto M.) van|||/items/85600314-f061-4c21-8022-54570fcef98bSchulz, C. (Christian)|||/items/4ada632f-ec3f-4ffe-abdd-a92f14536260Schütte, K. (Kerstin)|||/items/5b03b17f-f4d0-43da-942b-c4b939ec1d59Iezzi, R. (Roberto)|||/items/91472f31-aae7-42fe-ac92-c228c63f762dPech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471fMalfertheiner, P. (Peter)|||/items/7d7ba999-c5c6-4cf5-9cd3-1dffd4d4d26dSangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49Ricke, J. (Jeans)|||/items/3bfc1d9c-b91e-4e2f-99ca-959622b33e38Seidensticker, M. (Max)|||/items/5365aab8-55e0-458c-85f0-ff43e3b91270Gadoxetic acidHepatocellular carcinomaRadioembolizationSorafenibWNTß-CateninHepatologíaPurpose: Gadoxetic acid uptake on hepatobiliary phase MRI has been shown to correlate with ß-catenin mutation in patients with HCC, which is associated with resistance to certain therapies. This study aimed to evaluate the prognostic value of gadoxetic acid uptake on hepatobiliary phase MRI in patients with advanced HCC receiving sorafenib. Methods: 312 patients with available baseline hepatobiliary phase MRI images received sorafenib alone or following selective internal radiation therapy (SIRT) within SORAMIC trial. The signal intensity of index tumor and normal liver parenchyma were measured on the native and hepatobiliary phase MRI images, and relative tumor enhancement higher than relative liver enhancement were accepted as high gadoxetic acid uptake, and its prognostic value was assessed using univariate and multivariate Cox proportional hazard models. Results: The median OS of the study population was 13.4 (11.8-14.5) months. High gadoxetic acid uptake was seen in 51 (16.3%) patients, and none of the baseline characteristics was associated with high uptake. In univariate analysis, high gadoxetic acid uptake was significantly associated with shorter overall survival (10.7 vs. 14.0 months, p = 0.005). Multivariate analysis confirmed independent prognostic value of high gadoxetic acid uptake (HR, 1.7 [1.21-2.3], p = 0.002), as well as Child-Pugh class (p = 0.033), tumor diameter (p = 0.002), and ALBI grade (p = 0.015). Conclusion: In advanced HCC patients receiving sorafenib (alone or combined with SIRT), high gadoxetic acid uptake of the tumor on pretreatment MRI, a surrogate of ß-catenin mutation, correlates with shorter survival. Gadoxetic acid uptake status might serve in treatment decision-making process.Springer NatureDadun. Depósito Académico Digital Universidad de Navarra20222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/118732reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1187322026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| title |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| spellingShingle |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial Öcal, O. (Osman)|||/items/e20f890d-387b-4b27-8cd2-bc265d1c07bb Gadoxetic acid Hepatocellular carcinoma Radioembolization Sorafenib WNT ß-Catenin Hepatología |
| title_short |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| title_full |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| title_fullStr |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| title_full_unstemmed |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| title_sort |
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
| dc.creator.none.fl_str_mv |
Öcal, O. (Osman)|||/items/e20f890d-387b-4b27-8cd2-bc265d1c07bb Rössler, D. (Daniel)|||/items/dfe8430c-6249-4c20-a1c3-e208c2cdcbb8 Gasbarrini, A. (Antonio)|||/items/abf16136-3e15-4dc4-898a-37218b06e35c Berg, T. (Thomas)|||/items/b24d8023-a52b-43bc-aae1-2eb6903e97a1 Klümpen, H. (Heinz)|||/items/6bb3d4b6-7e18-4aee-82af-296199525b09 Bargellini, I. (Irene)|||/items/2c302084-c5c3-4f12-8876-fc1da43d1c03 Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Delden, O.M. (Otto M.) van|||/items/85600314-f061-4c21-8022-54570fcef98b Schulz, C. (Christian)|||/items/4ada632f-ec3f-4ffe-abdd-a92f14536260 Schütte, K. (Kerstin)|||/items/5b03b17f-f4d0-43da-942b-c4b939ec1d59 Iezzi, R. (Roberto)|||/items/91472f31-aae7-42fe-ac92-c228c63f762d Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Malfertheiner, P. (Peter)|||/items/7d7ba999-c5c6-4cf5-9cd3-1dffd4d4d26d Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Ricke, J. (Jeans)|||/items/3bfc1d9c-b91e-4e2f-99ca-959622b33e38 Seidensticker, M. (Max)|||/items/5365aab8-55e0-458c-85f0-ff43e3b91270 |
| author |
Öcal, O. (Osman)|||/items/e20f890d-387b-4b27-8cd2-bc265d1c07bb |
| author_facet |
Öcal, O. (Osman)|||/items/e20f890d-387b-4b27-8cd2-bc265d1c07bb Rössler, D. (Daniel)|||/items/dfe8430c-6249-4c20-a1c3-e208c2cdcbb8 Gasbarrini, A. (Antonio)|||/items/abf16136-3e15-4dc4-898a-37218b06e35c Berg, T. (Thomas)|||/items/b24d8023-a52b-43bc-aae1-2eb6903e97a1 Klümpen, H. (Heinz)|||/items/6bb3d4b6-7e18-4aee-82af-296199525b09 Bargellini, I. (Irene)|||/items/2c302084-c5c3-4f12-8876-fc1da43d1c03 Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Delden, O.M. (Otto M.) van|||/items/85600314-f061-4c21-8022-54570fcef98b Schulz, C. (Christian)|||/items/4ada632f-ec3f-4ffe-abdd-a92f14536260 Schütte, K. (Kerstin)|||/items/5b03b17f-f4d0-43da-942b-c4b939ec1d59 Iezzi, R. (Roberto)|||/items/91472f31-aae7-42fe-ac92-c228c63f762d Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Malfertheiner, P. (Peter)|||/items/7d7ba999-c5c6-4cf5-9cd3-1dffd4d4d26d Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Ricke, J. (Jeans)|||/items/3bfc1d9c-b91e-4e2f-99ca-959622b33e38 Seidensticker, M. (Max)|||/items/5365aab8-55e0-458c-85f0-ff43e3b91270 |
| author_role |
author |
| author2 |
Rössler, D. (Daniel)|||/items/dfe8430c-6249-4c20-a1c3-e208c2cdcbb8 Gasbarrini, A. (Antonio)|||/items/abf16136-3e15-4dc4-898a-37218b06e35c Berg, T. (Thomas)|||/items/b24d8023-a52b-43bc-aae1-2eb6903e97a1 Klümpen, H. (Heinz)|||/items/6bb3d4b6-7e18-4aee-82af-296199525b09 Bargellini, I. (Irene)|||/items/2c302084-c5c3-4f12-8876-fc1da43d1c03 Peynircioglu, B. (Bora)|||/items/fca68796-d81a-436f-b61d-f6738027cc16 Delden, O.M. (Otto M.) van|||/items/85600314-f061-4c21-8022-54570fcef98b Schulz, C. (Christian)|||/items/4ada632f-ec3f-4ffe-abdd-a92f14536260 Schütte, K. (Kerstin)|||/items/5b03b17f-f4d0-43da-942b-c4b939ec1d59 Iezzi, R. (Roberto)|||/items/91472f31-aae7-42fe-ac92-c228c63f762d Pech, M. (Maciej)|||/items/3952e467-7f56-4131-afac-c7864104471f Malfertheiner, P. (Peter)|||/items/7d7ba999-c5c6-4cf5-9cd3-1dffd4d4d26d Sangro-Gómez-Acebo, B.C. (Bruno Carlos)|||/items/594bbdbb-046a-4ab2-878c-cb4fe577af49 Ricke, J. (Jeans)|||/items/3bfc1d9c-b91e-4e2f-99ca-959622b33e38 Seidensticker, M. (Max)|||/items/5365aab8-55e0-458c-85f0-ff43e3b91270 |
| author2_role |
author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
Gadoxetic acid Hepatocellular carcinoma Radioembolization Sorafenib WNT ß-Catenin Hepatología |
| topic |
Gadoxetic acid Hepatocellular carcinoma Radioembolization Sorafenib WNT ß-Catenin Hepatología |
| description |
Purpose: Gadoxetic acid uptake on hepatobiliary phase MRI has been shown to correlate with ß-catenin mutation in patients with HCC, which is associated with resistance to certain therapies. This study aimed to evaluate the prognostic value of gadoxetic acid uptake on hepatobiliary phase MRI in patients with advanced HCC receiving sorafenib. Methods: 312 patients with available baseline hepatobiliary phase MRI images received sorafenib alone or following selective internal radiation therapy (SIRT) within SORAMIC trial. The signal intensity of index tumor and normal liver parenchyma were measured on the native and hepatobiliary phase MRI images, and relative tumor enhancement higher than relative liver enhancement were accepted as high gadoxetic acid uptake, and its prognostic value was assessed using univariate and multivariate Cox proportional hazard models. Results: The median OS of the study population was 13.4 (11.8-14.5) months. High gadoxetic acid uptake was seen in 51 (16.3%) patients, and none of the baseline characteristics was associated with high uptake. In univariate analysis, high gadoxetic acid uptake was significantly associated with shorter overall survival (10.7 vs. 14.0 months, p = 0.005). Multivariate analysis confirmed independent prognostic value of high gadoxetic acid uptake (HR, 1.7 [1.21-2.3], p = 0.002), as well as Child-Pugh class (p = 0.033), tumor diameter (p = 0.002), and ALBI grade (p = 0.015). Conclusion: In advanced HCC patients receiving sorafenib (alone or combined with SIRT), high gadoxetic acid uptake of the tumor on pretreatment MRI, a surrogate of ß-catenin mutation, correlates with shorter survival. Gadoxetic acid uptake status might serve in treatment decision-making process. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2022-01-01 2022 2022-01-01 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/118732 |
| url |
https://hdl.handle.net/10171/118732 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Springer Nature |
| publisher.none.fl_str_mv |
Springer Nature |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Consejo Superior de Investigaciones Científicas (CSIC) |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869424339498041344 |
| score |
15,81155 |